By / May 29, 2020

Medical cannabis legalization has reduced pain-killers consumption in the US

A new study found that in the US states which allowed medical cannabis during the past months, there was an average annual decrease of about 20% in prescriptions for analgesics, between 2013 – 2017. Meanwhile, in the US states where medical cannabis is prohibited, there was a mere 1.7% decline.

If you want to know more about cannabis, how cannabis legalization is affecting medical drug consumption in the United States, and to find out the latest cannabis news, download the mobile application.

Cannabis as an alternative to the common analgesics

“The misuse of drugs and the large number of prescriptions given to them are still a significant national problem,” is the study’s explanation, which was published earlier this month in the American Academy of Orthopedic Surgeons. The study specifically addresses prescriptions given by orthopedic surgeons, who are among the doctors who prescribe the most drugs in the United States.

“Cannabinoids provide orthopedic patients with an alternative to drug painkillers in 32 US states that have approved medical use,” the researchers wrote. “Therefore, in this study we looked at how the amount of drug prescriptions given to patients between 2013-2017 has changed in countries where medical cannabis was legalized, compared to the states where the use of medical cannabis is not yet legal,” they concluded.

The researchers calculated for each country the number of daily doses of drugs in the period under review. The amount of drug that is defined as a daily dose is calculated specifically for each patient. For example, if the patient is taking 2 pills a day and has been given a prescription for 30 pills, this prescription is 15 daily doses of the drug.

Medical cannabis as a treatment alternative

The US states where people have access to medical cannabis, registered an average annual decrease of 144,000 (or 19.7%) daily doses of drug painkillers between 2013 and 2017. In contrast, in the US states where there was no medical cannabis legislation during these years, there was no significant change in the daily dose, but only a minimal decrease (1.7%) that could not be attributed to statistical significance.

The researchers not only examined the cannabis laws of each state on paper, but also their actual application. As expected, they found that in states that have approved medical cannabis legislation but have not yet decided where the actual stores should be located, there has been no significant change in the number of drug prescriptions. The decline in drug prescriptions has only been observed in states where patients could purchase medical cannabis in stores, and not just grow it themselves at home.

“These results are in line with some previous studies that have shown that states where medical cannabis is legal have seen a reduction in drug prescriptions as well as mortality rates from its use,” the authors noted.

Similar findings were previously obtained in a study conducted by University of Alabama published earlier this year in the Journal of Health Economics, as well as studies published in the Journal of the American Medical Association (JAMA) as early as 2018.


(Featured image by Steve Buissinne via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in קנאביס, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Comments are closed for this post.